痴呆症患者的卡塔托尼亚:临床概况和治疗反应的描述性研究
Vanina Ramognino1, Thomas Fovet2, Mathilde Horn2
1Univ. Lille, Inserm, CHU Lille, U1172 - LilNCog - Lille Neuroscience & Cognition, Lille F-59000, France; EPSM des Flandres Bailleul, France.
Asian journal of psychiatry
|April 2, 2024
概括
痴呆症常常伴随着白内障,虽然可以治疗,但对洛拉泽巴姆的反应因痴呆症类型而异. 需要进一步的研究,以了解和克服这些患者的治疗耐药性.
科学领域:
- 神经科学是一个神经科学.
- 老年精神病学是一门精神病学专业.
- 临床神经学 临床神经学
背景情况:
- 卡塔托尼症是患有主要神经认知障碍 (痴呆症) 个体的常见综合征.
- 了解痴呆症患者中猫症的临床和治疗方面至关重要.
研究的目的:
- 综合描述痴呆症患者中猫的临床和治疗特征.
- 识别影响治疗反应和耐药性的因素.
主要方法:
- 从2015年9月到2022年6月进行了一项描述性研究.
- 收集了25名被诊断患有白内障的痴呆症患者的数据,包括社会人口统计,临床和治疗信息.
主要成果:
- 痴呆症患者占 catatonia 病例的 17%,平均年龄为 65 岁,主要是女性参与者.
- 常见的痴呆症诊断包括前叶退化 (41%),莱维体痴呆症 (21%),阿尔茨海默病 (17%) 和血管痴呆症 (17%).
- 在75%的患者中实现了完整的性衰竭缓解,通常需要除洛拉泽帕之外的干预措施,例如电疗法 (ECT) 和阿曼塔丁;血管痴呆病例显示出更高的耐药性.
结论:
- 猫头和痴呆症经常同时发生,猫头在这个人群中是可以治疗的.
- 根据特定的痴呆症诊断,洛拉泽巴姆的反应有很大差异,血管性痴呆症病例比较耐药.
- 进一步研究洛拉泽帕姆耐药性和治疗变异性的机制对于开发有针对性的治疗策略至关重要.
更多相关视频
07:26Characterizing the Relationship Between Eye Movement Parameters and Cognitive Functions in Non-demented Parkinson's Disease Patients with Eye Tracking
Published on: September 26, 2019
7.8K
10:41Implantation of Osmotic Pumps and Induction of Stress to Establish a Symptomatic, Pharmacological Mouse Model for DYT/PARK-ATP1A3 Dystonia
Published on: September 12, 2020
7.4K
相关概念视频
01:24Parkinson's Disease: Treatment
264
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
264
01:26Psychosis: Goals of Pharmacotherapy
125
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
125
01:22Alzheimer's Disease: Treatment
184
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
184
01:28Psychosis and Antipsychotic Drugs: Overview
248
The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic...
248
01:28Drug Therapy
43
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
43
01:15Parkinson's Disease: Overview
541
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
541